If an individual was to accept that LDX will likely achieve their short/medium term goals, then this analysis from an online article shows the upside potential available with the LDX share price.
According to the article:
- LDX has a price-to-sales (PS ratio) ratio of 1.3x
- half of all ASX med-tech companies have a PS ratio of 4.1x
- a PS ration of 15x are not unusual for med-tech stocks on the ASX
So, at a PS ratio of 1.3x, LDX can triple in share price and still be below the average PS ratio for med-tech stocks on the ASX, and can 12-times its current value and still be in-line with the PS ration of many med-tech stocks on the ASX.Current LDX share price is 3 cents per share multiplied by the above stated PS ratios:
$0.03 cents*3 = $0.09 cents per share
$0.03 cents*12 = $0.36 cents per share
IMO, LDX is significantly undervalued and has a lot of upside potential.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $20.21M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 318288 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 45000 | 2 |
View Market Depth
| Last trade - 09.56am 18/06/2025 (20 minute delay) ? |
| LDX (ASX) Chart |
Day chart unavailable